AI
Commented by André Will-Laudien on October 7th, 2025 | 07:00 CEST
Total boom! Not 10% returns per year, but per day! The portfolio rockets: Almonty, Plug Power, Nel ASA and AMD
The financial markets are in a bullish mood. But not all stocks are performing like Almonty Industries, where the surge is driven purely by fundamental revaluation. After the gold rush in 2020/2021, hydrogen stocks underwent a prolonged 95% correction. For US industry leader Plug Power, this meant a sell-off from over USD 12 to a low of USD 0.75. In May, the correction came to an end, and the stock skyrocketed to over USD 4.75 yesterday – a fivefold increase in just four months. Nel ASA has followed a similar path, with a 15% turnaround from the bottom yesterday. These extreme movements are evidence of very high market liquidity. AMD surprised with a deal with OpenAI - fueling a 25% jump. The helium balloon keeps rising. Here is an overview of the action.
Read
Commented by André Will-Laudien on October 2nd, 2025 | 07:25 CEST
AI fuels cancer research: Bayer, Vidac Pharma, and Pfizer are the next 150% winners
The stock market remains strong! In addition to the tech and defense boom, the biotech sector has also been catching up in recent days, with the latest news in cancer research bringing the industry back into the spotlight. The key factor here is artificial intelligence, which is revolutionizing cancer research through personalized therapy approaches based on the evaluation of extensive clinical and genetic data. AI models make it possible to predict individual cancer progression better and tailor therapies to individual patients. By analyzing multimodal data, AI systems can more accurately assess the risk of metastasis and thus develop targeted treatment strategies. AI has also improved tumor diagnostics by accurately detecting numerous types of cancer, therefore ensuring a more precise diagnosis.
Read
Commented by Carsten Mainitz on October 2nd, 2025 | 07:10 CEST
NetraMark Holdings, Evotec, Sartorius – Billion-dollar deals in sight!
Artificial intelligence and machine learning have become key drivers across nearly every industry. When pharmaceutical companies successfully develop a drug to market readiness, profits can surge. However, only a few active ingredients that enter clinical trials ultimately receive approval. It is therefore a long, risky, and costly process. The use of AI can help to minimize these risks significantly. Here, we take a look at the potential of AI-based strategies among established players Evotec and Sartorius, with a particular focus on the innovative approach of Canadian company NetraMark Holdings.
Read
Commented by André Will-Laudien on September 30th, 2025 | 07:35 CEST
High-tech super boom! 1,000% no problem—here is more from D-Wave, NetraMark and Palantir!
Artificial intelligence (AI) is currently revolutionizing drug development by analyzing enormous amounts of data in a very short time and making clinical trials much more targeted. Modern AI systems make it possible to select drug candidates with precision and predict the potential success of a therapy with a high degree of accuracy. Companies like NetraMark are already using these technologies profitably. Players such as D-Wave and Palantir are also among the pioneers of the new AI-driven economy and have seen their share prices rise by over 1,000%. Expectations for further growth are virtually limitless. The advent of quantum computer technology also marks the beginning of a new chapter in ultra-fast data processing. For forward-looking investors, this opens up attractive entry opportunities in dynamically expanding future markets. Those who bet on the right players early on can benefit from this change to an above-average extent.
Read
Commented by Stefan Feulner on September 29th, 2025 | 07:05 CEST
SAP, Aspermont, AppLovin – AI models with powerful upward momentum
The combination of big data and artificial intelligence is considered one of the biggest growth drivers of the coming decade. Companies that manage to efficiently collect and evaluate vast amounts of data and make it usable in real time not only gain competitive advantages but also redefine entire industries. Whether in healthcare, finance, commodities, or industry, those who use data intelligently can optimize processes, reduce costs, and develop entirely new business models. Investors should not underestimate this dynamic.
Read
Commented by Nico Popp on September 26th, 2025 | 07:30 CEST
AI is conquering increasingly more areas: SAP and Amazon are targeting small and mid-sized businesses, while NetraMark is winning over the biotech industry
Will AI become our new god? This question is currently being explored in depth by the German philosopher Markus Gabriel in a well-known German podcast. And although the question may cause unease for many, Gabriel's conclusions are ultimately anything but pessimistic. SAP and Amazon are also looking to the future with optimism: Together with OpenAI, they are now building an AI infrastructure in Germany. The goal: to enable public authorities and companies to use the latest AI tools in a legally compliant manner, without European data leaving the continent. The initiative demonstrates that AI will conquer many more areas in the coming years. One of these areas is medical research. The innovative company NetraMark is using its AI solution to deliver faster results and lower costs for future-focused projects, such as the fight against cancer.
Read
Commented by Nico Popp on September 23rd, 2025 | 07:10 CEST
The AI doctor in your pocket: PanGenomic Health, Bayer, CVS Health
Healthcare costs are a pressing political issue worldwide - in Germany, for example, debates are resurfacing over co-payments and the requirement to see a general practitioner first. This drives more people to self-medicate. The situation is even more extreme in the US: without mandatory insurance and facing extremely high healthcare costs, almost 9% of the population is uninsured, and around 33% is underinsured, leading many citizens to turn to alternative solutions. We examine business models related to increasing personal responsibility in healthcare, with a special focus on a smaller-cap stock.
Read
Commented by Fabian Lorenz on September 18th, 2025 | 07:25 CEST
Adidas to take over Puma? Evotec with insider buying! 50% upside potential with AI stock NetraMark!
Adidas and Puma caught in merger fever? A US investor brings the spectacular idea into play. Is it a means of exerting pressure on Puma's management or a real possibility? What do analysts say? Meanwhile, Evotec is sending a signal of confidence with fresh insider purchases. However, the stock is still digesting the recent revenue forecast downgrade. Could there be fresh momentum next week? In contrast, NetraMark shares offer a 50% return. For this to happen, however, the AI-driven drug development specialist must reach the analysts' price target. Operationally, there is much to be said for this, and in comparative tests, the Company has outperformed ChatGPT and DeepSeek.
Read
Commented by Stefan Feulner on September 16th, 2025 | 07:25 CEST
Broadcom, NetraMark, Adobe – The AI wave continues to roll inexorably forward
Artificial intelligence is more than just hype; it is becoming the central driver of innovation in our time. Whether in industry, medicine, mobility, or finance, this technology is changing processes, increasing efficiency and creating new business models in almost all sectors. Companies that embrace AI early on secure clear competitive advantages. At the same time, a future market with enormous potential is opening up for investors. However, despite the rosy outlook, stock picking is also required here, as many companies are significantly overvalued.
Read
Commented by Armin Schulz on September 16th, 2025 | 07:20 CEST
Building wealth with network effects and AI: How Palantir, MiMedia, and Alibaba are making investors rich
The global economy is being driven by a new type of company: scalable platform ecosystems with predictable, recurring revenues. They leverage network effects for exponential growth and are resilient to economic fluctuations. These disruptive business models, at the intersection of AI, data, and digital connectivity, generate steady cash flows and define the investment opportunities of tomorrow. Three companies that perfectly embody this strategy are Palantir, MiMedia Holdings and Alibaba.
Read